Omalizumab for treatment of refractory urticaria in a patient with metastatic uveal melanoma receiving tebentafusp
{{output}}
Tebentafusp is an immune-mobilizing monoclonal T-cell receptor approved for the treatment of metastatic uveal melanoma. While this agent improves outcomes in patients with unresectable or metastatic uveal melanoma, tebentafusp commonly results in dermatologic ... ...
